Press Releases.

--Final data and potential for $25m milestone anticipated in H1 2023--

Company remains on track to submit IND and initiate Phase 1 study in second quarter 2022

Definitive Agreement for $34.6 Million in Gross Proceeds

-Company advances RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)-

-Company will advance RGLS8429 supported by strong preclinical data and superior pharmacologic profile as compared to first-generation RGLS4326-

Completed Preparations and Request for FDA Meeting to Obtain Feedback on Approach to Addressing Remaining Hold Requirements

--Company also Announces Participation in a Panel Discussion at the 2021 Wedbush PacGrow Healthcare Conference

Study demonstrates clinical proof of mechanism with statistically significant increases in polycystin levels following RGLS4326 treatment in the first cohort of patients with ADPKD

Data to Be Presented Today at the Oppenheimer Rare & Orphan Disease Summit

Regulus Therapeutics Demonstrates Target Engagement in First-Ever Study of RGLS4326 in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Demonstrated Pharmacokinetic Profile Similar to Healthy Volunteers

Completed Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD")

Definitive Agreement for $19.4 Million in Gross Proceeds

First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD")

Regulus to Receive Remaining $5 Million Payment for Enrollment Milestone

Proceeds Used to Repay Debt Principal with Oxford Finance

Completion of Dosing in Phase 1 Multiple Ascending Dose Study ("MAD") of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease ("ADPKD")